Continuing the Conversation: Optimizing Fibrosing ILD Outcomes: A Pharmacist-Led Approach to Evidence-Based Care

Program Description

Fibrosing interstitial lung diseases (F-ILDs) include idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and systemic autoimmune rheumatic disease-associated ILD (SARD-ILD). These conditions remain among the most challenging in pulmonary care and are marked by irreversible loss of lung function, frequent misdiagnosis, and poor long-term prognosis. Many patients discontinue treatment due to tolerability issues, and a substantial proportion do not receive guideline-recommended care. The therapeutic landscape now includes recently approved and late-stage antifibrotic and anti-inflammatory agents shown to slow disease progression, as well as opportunities for how and when to apply combination strategies across IPF, PPF, and SARD-ILD. As specialty and health-system pharmacists take on growing roles in diagnosis support, medication management, and adverse effect monitoring for these patients, they need current, practical guidance on distinguishing ILD subtypes, applying the latest recommendations, and navigating real-world challenges in adherence, safety, and access. This case-based session gives pharmacists the tools to navigate this landscape. Discussion around real-world patient scenarios will walk pharmacists through how to recognize early signs of disease progression, apply guideline-directed and emerging therapies, and manage the adherence, safety, and access barriers that shape real-world outcomes. Participants will be able to download additional materials, including a Train-the-Trainer component that provides customizable tools for pharmacy leaders to disseminate these plans across their institutions.

Target audience: Health-System pharmacists, Consultant pharmacists, Specialty pharmacists
Type of activity: Application
Release date: December 3, 2026
Expiration date: February 3, 2027
Time to complete activity: 1 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the impact of idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) on morbidity, mortality, and quality of life and opportunities for improved management
• Analyze current guideline recommendations and clinical evidence for approved and emerging therapies for IPF, PPF, and SARD-ILD
• Identify pharmacist-driven strategies in collaborative care models to enhance adherence, safety monitoring, and clinical outcomes in fibrosing ILDs

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-290-L01-P. The activity is available for CE credit through February 3, 2027.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.

Disclosures

Jessica L. Wallace, PharmD, BCPS, has no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Emily Tyler; and Brianna Winters have no financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms